Rockwell Medical, Inc. (RMTI) stock
RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3080% below fair value
$6.61−0.15 (-2.22%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Rockwell Medical r&d expenses
Research and development expenses are spending on new products and technology.
Rockwell Medical's R&D Expenses for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $48.27M in fiscal 2012.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $19.00K | -98.3% |
| FY2023 | Dec 31, 2023 | $1.11M | -64.5% |
| FY2022 | Dec 31, 2022 | $3.12M | -54.4% |
| FY2021 | Dec 31, 2021 | $6.84M | -3.6% |
| FY2020 | Dec 31, 2020 | $7.09M | +3.0% |
| FY2019 | Dec 31, 2019 | $6.89M | +22.0% |
| FY2018 | Dec 31, 2018 | $5.64M | -10.7% |
| FY2017 | Dec 31, 2017 | $6.32M | +8.2% |
| FY2016 | Dec 31, 2016 | $5.84M | +17.7% |
| FY2015 | Dec 31, 2015 | $4.96M | -36.3% |
| FY2014 | Dec 31, 2014 | $7.78M | -80.2% |
| FY2013 | Dec 31, 2013 | $39.38M | -18.4% |
| FY2012 | Dec 31, 2012 | $48.27M | +171.1% |
| FY2011 | Dec 31, 2011 | $17.81M | +420.3% |
| FY2010 | Dec 31, 2010 | $3.42M | -47.0% |
| FY2009 | Dec 31, 2009 | $6.45M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $40.00K | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.00K | -99.4% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $18.00K | -93.5% |
| Q4 FY2023 | Dec 31, 2023 | $168.00K | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $494.00K | +5.3% |
| Q2 FY2023 | Jun 30, 2023 | $167.00K | -82.0% |
| Q1 FY2023 | Mar 31, 2023 | $278.00K | -82.3% |
| Q4 FY2022 | Dec 31, 2022 | $156.00K | -88.8% |
| Q3 FY2022 | Sep 30, 2022 | $469.00K | -61.6% |
| Q2 FY2022 | Jun 30, 2022 | $926.00K | -61.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.57M | -13.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.39M | -27.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.22M | -30.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.42M | +49.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.81M | -0.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.91M | -2.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.75M | +18.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.62M | -45.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.82M | +266.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.96M | +21.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.48M | +82.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.96M | +89.8% |
| Q1 FY2019 | Mar 31, 2019 | $497.28K | -70.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.61M | -24.3% |
| Q3 FY2018 | Sep 30, 2018 | $808.19K | -38.1% |
| Q2 FY2018 | Jun 30, 2018 | $1.56M | -7.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.67M | +37.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.13M | +77.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.30M | +3.4% |
| Q2 FY2017 | Jun 30, 2017 | $1.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.21M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.26M | – |
See a number that looks wrong?